Regulatory News In Brief
This article was originally published in The Tan Sheet
Executive Summary
FDA denies PSE market removal petition; Alabama drug offender registry bolsters NPLEx; FDA issues advisories on three products spiked with ED ingredient; advocacy group joins homeopathic lawsuit in Canada against Boiron.
You may also be interested in...
In Brief
FDA proposes amending ANDA-blocking petition reg; Sara Lee snaps up Tea Forté; testing by FDA, CDC find no bacteria in Enfamil formula powder; USP offers draft probiotics standards; more news In Brief.
FDA Supplement Enforcement Priorities Go Beyond NDI Notification
FDA’s plan to tighten enforcement of new dietary ingredient notifications with its controversial guidance still in draft form raises concerns for some stakeholders.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.